Neobiotic may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Neobiotic in the following countries:
International Drug Name Search
Generic Name: drotrecogin alfa (droe tre KOE gin AL fa)
Brand Names: Xigris
Drotrecogin alfa is a form of human protein (Protein C).
Drotrecogin alfa is used to treat sepsis in patients who have a high risk of death due to multi-system organ failure.
Drotrecogin alfa was withdrawn from the U.S. market in October 2011.
Drotrecogin alfa may also be used for purposes not listed in this medication guide.
You should not receive this medication if you have active internal bleeding, brain cancer, tumor, or bleeding in the brain. You should also not receive drotrecogin alfa if you have had brain or spine surgery or a head injury in the past 2 months, or if you have had a stroke within the past 3 months.
Before receiving drotrecogin alfa, tell your doctor if you have severe liver disease, a bleeding or blood clotting disorder, if you have recently had stomach or intestinal bleeding, or have recently taken aspirin, a blood-thinner, or medications to treat or prevent blood clots.
active internal bleeding;
brain cancer, tumor, or bleeding in the brain;
if you have had brain or spine surgery or a head injury in the past 2 months; or
if you have had a stroke within the past 3 months.
Before you receive drotrecogin alfa, tell your doctor if you are allergic to any drugs, or if you have:
severe liver disease;
a bleeding or blood clotting disorder;
if you have had stomach or intestinal bleeding within the past 6 weeks;
if you have received treatment for blood clots within the past 3 days; or
if you have taken aspirin or a blood thinner (such as warfarin, Coumadin), or anti-platelet medication (dipyridamole, Persantine, clopidogrel, Plavix) within the past 7 days.
If you have any of these conditions, you may need a dose adjustment or special tests to safely receive drotrecogin alfa.
Drotrecogin alfa is given as an injection through a needle placed into a vein. You will most likely receive this injection in a hospital setting.
Drotrecogin alfa must be given slowly through an IV infusion, and can take up to 4 days to complete.
Since drotrecogin alfa is given as needed by a healthcare professional, it is not likely that you will miss a dose.
Overdose symptoms may include unusual bleeding, or any bleeding that won't stop.
Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are receiving drotrecogin alfa..
blood in your urine or stools;
coughing up blood or vomit that looks like coffee grounds;
bleeding from any incision or injection in your skin; or
any bleeding that won't stop.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Sepsis:
Drotrecogin alfa was voluntarily withdrawn from the market by the manufacturer in October, 2011 due to failure to show a survival benefit for patients with severe sepsis and septic shock. The following dosage information applies to when the drug was available in the U.S.
24 mcg/kg/hr by intravenous infusion for 96 hours
Usual Pediatric Dose for Sepsis:
Drotrecogin alfa was voluntarily withdrawn from the market by the manufacturer in October, 2011 due to failure to show a survival benefit for patients with severe sepsis and septic shock. The following dosage information applies to when the drug was available in the U.S.
Multiple study data:
0 to 18 years: 24 mcg/kg/hr by intravenous infusion for 96 hours.
Before receiving drotrecogin alfa, tell your doctor if you have recently received any of the following medications prevent blood clots:
alteplase (Activase);
anistreplase (Eminase);
clopidogrel (Plavix);
dipyridamole (Persantine);
streptokinase (Kabikinase, Streptase);
ticlopidine (Ticlid);
urokinase (Abbokinase).
This list is not complete and there may be other drugs that can interact with drotrecogin alfa. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: drotrecogin alfa side effects (in more detail)
NeoCitran Hustenlöser may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of NeoCitran Hustenlöser in the following countries:
International Drug Name Search
Sacvercot may be available in the countries listed below.
Probucol is reported as an ingredient of Sacvercot in the following countries:
International Drug Name Search
Axcef may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Axcef in the following countries:
International Drug Name Search
Mirrador may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Mirrador in the following countries:
International Drug Name Search
Acide Tiaprofénique Teva may be available in the countries listed below.
Tiaprofenic Acid is reported as an ingredient of Acide Tiaprofénique Teva in the following countries:
International Drug Name Search
MDB Flavo 4 may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Bambermycin is reported as an ingredient of MDB Flavo 4 in the following countries:
International Drug Name Search
In the US, Nasalcrom (cromolyn nasal) is a member of the drug class nasal antihistamines and decongestants and is used to treat Hay Fever.
US matches:
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Nasalcrom in the following countries:
International Drug Name Search
Finascar may be available in the countries listed below.
Finasteride is reported as an ingredient of Finascar in the following countries:
International Drug Name Search
Nylex may be available in the countries listed below.
Calcitonin is reported as an ingredient of Nylex in the following countries:
International Drug Name Search
Dapson-Fatol may be available in the countries listed below.
Dapsone is reported as an ingredient of Dapson-Fatol in the following countries:
International Drug Name Search
Desferal is a brand name of deferoxamine, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Desferal:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Desferal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Desferal.
Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Trisenox available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
In the US, Voltaren (diclofenac systemic) is a member of the drug class nonsteroidal anti-inflammatory agents and is used to treat Ankylosing Spondylitis, Aseptic Necrosis, Back Pain, Frozen Shoulder, Muscle Pain, Osteoarthritis, Pain, Period Pain, Rheumatoid Arthritis and Sciatica.
US matches:
Diclofenac is reported as an ingredient of Voltaren in the following countries:
Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:
Diclofenac hydroxyethylpyrrolidine (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:
Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:
Diclofenac resinate (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:
International Drug Name Search
Bromocriptine Mesylate (USAN) is known as Bromocriptine in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
Carvedilol Jaba may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Jaba in the following countries:
International Drug Name Search
Cremor hydrocortisoni PCH may be available in the countries listed below.
Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Cremor hydrocortisoni PCH in the following countries:
International Drug Name Search
Fosinopril Basics may be available in the countries listed below.
Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril Basics in the following countries:
International Drug Name Search
N-Acetilcisteina La Santé may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of N-Acetilcisteina La Santé in the following countries:
International Drug Name Search
Ciclosterona may be available in the countries listed below.
Progesterone is reported as an ingredient of Ciclosterona in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Diphenhydramine/Phenylephrine Strips are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Diphenhydramine/Phenylephrine Strips. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some medical conditions may interact with Diphenhydramine/Phenylephrine Strips. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Diphenhydramine/Phenylephrine Strips may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Diphenhydramine/Phenylephrine Strips as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Diphenhydramine/Phenylephrine Strips.
All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; dry mouth; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision or other vision changes; difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; mood or mental changes; persistent trouble sleeping; restlessness; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; tremor.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Diphenhydramine/Phenylephrine side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular breathing; unusually fast, slow, or irregular heartbeat.
Store Diphenhydramine/Phenylephrine Strips at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diphenhydramine/Phenylephrine Strips out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Diphenhydramine/Phenylephrine Strips. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Locorten Vioform may be available in the countries listed below.
UK matches:
Clioquinol is reported as an ingredient of Locorten Vioform in the following countries:
Flumetasone 21-pivalate (a derivative of Flumetasone) is reported as an ingredient of Locorten Vioform in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Rx only
Under the Drug Addiction Treatment Act of 2000 (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence.
Buprenorphine hydrochloride sublingual tablets contains buprenorphine HCl.
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Buprenorphine is a Schedule III narcotic under the Controlled Substances Act.
Buprenorphine HCl is a white powder, weakly acidic with limited solubility in water (17 mg/mL). Chemically, buprenorphine is 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-α-methyl-6, 14-ethenomorphinan-7-methanol, hydrochloride [5α, 7α (S)]-. Buprenorphine hydrochloride has the molecular formula C29 H41 NO4 HCl and the molecular weight is 504.10.
.HCl
Buprenorphine HCl sublingual tablet is an uncoated round white tablet intended for sublingual administration. It is available in two dosage strengths, 2 mg buprenorphine and 8 mg buprenorphine free base. Each tablet also contains lactose monohydrate, mannitol, cornstarch, povidone K30, citric acid, sodium citrate anhydrous and sodium stearyl fumarate. The strengths are clearly marked on the tablets.
Comparisons of buprenorphine with full agonists such as methadone and hydromorphone suggest that sublingual buprenorphine produces typical opioid agonist effects which are limited by a ceiling effect.
In non-dependent subjects, acute sublingual doses of buprenorphine and naloxone sublingual tablets produced opioid agonist effects, which reached a maximum between doses of 8 mg and 16 mg of buprenorphine. The effects of 16 mg buprenorphine and naloxone sublingual tablets were similar to those produced by 16 mg buprenorphine HCl sublingual tablets (buprenorphine alone).
Opioid agonist ceiling effects were also observed in a double-blind, parallel group, dose ranging comparison of single doses of Buprenorphine Sublingual solution (1, 2, 4, 8, 16, or 32 mg), placebo, and a full agonist control at various doses. The treatments were given in ascending dose order at intervals of at least one week to 16 opioid-experienced, non-dependent subjects. Both drugs produced typical opioid agonist effects. For all the measures for which the drugs produced an effect, buprenorphine produced a dose-related response but, in each case, there was a dose that produced no further effect. In contrast, the highest dose of the full agonist control always produced the greatest effects. Agonist objective rating scores remained elevated for the higher doses of buprenorphine (8 to 32 mg) longer than for the lower doses and did not return to baseline until 48 hours after drug administrations. The onset of effects appeared more rapidly with buprenorphine than with the full agonist control, with most doses nearing peak effect after 100 minutes for buprenorphine compared to 150 minutes for the full agonist control.
Buprenorphine in intravenous (2 mg, 4 mg, 8 mg, 12 mg and 16 mg) and sublingual (12 mg) doses has been administered to non-dependent subjects to examine cardiovascular, respiratory and subjective effects at doses comparable to those used for treatment of opioid dependence. Compared with placebo, there were no statistically significant differences among any of the treatment conditions for blood pressure, heart rate, respiratory rate, O2 saturation or skin temperature across time. Systolic BP was higher in the 8 mg group than placebo (3 hour AUC values). Minimum and maximum effects were similar across all treatments. Subjects remained responsive to low voice and responded to computer prompts. Some subjects showed irritability, but no other changes were observed.
The respiratory effects of sublingual buprenorphine were compared with the effects of methadone in a double-blind, parallel group, dose ranging comparison of single doses of Buprenorphine Sublingual solution (1, 2, 4, 8, 16, or 32 mg) and oral methadone (15, 30, 45, or 60 mg) in non-dependent, opioid-experienced volunteers. In this study, hypoventilation not requiring medical intervention was reported more frequently after buprenorphine doses of 4 mg and higher than after methadone. Both drugs decreased O2 saturation to the same degree.
Physiologic and subjective effects following acute sublingual administration of buprenorphine and naloxone sublingual tablets and buprenorphine HCl sublingual tablets were similar at equivalent dose levels of buprenorphine. Naloxone, in the buprenorphine and naloxone sublingual tablets formulation, had no clinically significant effect when administered by the sublingual route, although blood levels of the drug were measurable.
Plasma levels of buprenorphine increased with the sublingual dose of buprenorphine HCl sublingual tablets and buprenorphine and naloxone sublingual tablets, and plasma levels of naloxone increased with the sublingual dose of buprenorphine and naloxone sublingual tablets (Table 1). There was a wide inter-patient variability in the sublingual absorption of buprenorphine and naloxone, but within subjects the variability was low. Both Cmax and AUC of buprenorphine increased in a linear fashion with the increase in dose (in the range of 4 to 16 mg), although the increase was not directly dose-proportional.
Naloxone did not affect the pharmacokinetics of buprenorphine and both buprenorphine HCl sublingual tablets and buprenorphine and naloxone sublingual tablets deliver similar plasma concentrations of buprenorphine. The levels of naloxone were too low to assess dose-proportionality. At the three naloxone doses of 1 mg, 2 mg, and 4 mg, levels above the limit of quantitation (0.05 ng/mL) were not detected beyond 2 hours in seven of eight subjects. In one individual, at the 4 mg dose, the last measurable concentration was at 8 hours. Within each subject (for most of the subjects), across the doses there was a trend toward an increase in naloxone concentrations with increase in dose. Mean peak naloxone levels ranged from 0.11 to 0.28 ng/mL in the dose range of 1 to 4 mg.
| Pharmacokinetic Parameter | buprenorphine and naloxone sublingual tablets 4 mg | buprenorphine and naloxone sublingual tablets 8 mg | buprenorphine and naloxone sublingual tablets 16 mg | Buprenorphine HCl sublingual tablets 16 mg |
|---|---|---|---|---|
| Cmax, ng/mL | 1.84 (39) | 3.0 (51) | 5.95 (38) | 5.47 (23) |
| AUC 0-48, hour. ng/mL | 12.52 (35) | 20.22 (43) | 34.89 (33) | 32.63 (25) |
Buprenorphine is approximately 96% protein bound, primarily to alpha and beta globulin.
Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated by cytochrome P-450 3A4 isozyme. Norbuprenorphine, an active metabolite, can further undergo glucuronidation.
A mass balance study of buprenorphine showed complete recovery of radiolabel in urine (30%) and feces (69%) collected up to 11 days after dosing. Almost all of the dose was accounted for in terms of buprenorphine, norbuprenorphine, and two unidentified buprenorphine metabolites. In urine, most of buprenorphine and norbuprenorphine was conjugated (buprenorphine, 1% free and 9.4% conjugated; norbuprenorphine, 2.7% free and 11% conjugated). In feces, almost all of the buprenorphine and norbuprenorphine were free (buprenorphine, 33% free and 5% conjugated; norbuprenorphine, 21% free and 2% conjugated).
Buprenorphine has a mean elimination half-life from plasma of 37 h.
The effect of hepatic impairment on the pharmacokinetics of buprenorphine is unknown. Since this drug is extensively metabolized, the plasma levels will be expected to be higher in patients with moderate and severe hepatic impairment. Therefore, in patients with hepatic impairment dosage should be adjusted and patients should be observed for symptoms of precipitated opioid withdrawal.
No differences in buprenorphine pharmacokinetics were observed between 9 dialysis-dependent and 6 normal patients following intravenous administration of 0.3 mg buprenorphine.
The effects of renal failure on naloxone pharmacokinetics are unknown.
CYP 3A4 Inhibitors and Inducers: A pharmacokinetic interaction study of ketoconazole (400 mg/day), a potent inhibitor of CYP 3A4, in 12 patients stabilized on buprenorphine and naloxone sublingual tablets [8 mg (n=1) or 12 mg (n=5) or 16 mg (n=6)] resulted in increases in buprenorphine mean Cmax values (from 4.3 to 9.8, 6.3 to 14.4 and 9.0 to 17.1) and mean AUC values (from 30.9 to 46.9, 41.9 to 83.2 and 52.3 to 120) respectively. Subjects receiving buprenorphine HCl sublingual tablets should be closely monitored and may require dose-reduction if inhibitors of CYP 3A4 such as azole antifungal agents (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin) and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) are co-administered. The interaction of buprenorphine with CYP 3A4 inducers has not been investigated; therefore it is recommended that patients receiving buprenorphine HCl sublingual tablets should be closely monitored if inducers of CYP 3A4 (e.g., phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered (SEE WARNINGS).
Clinical data on the safety and efficacy of buprenorphine HCl sublingual tablets are derived from studies of Buprenorphine Sublingual tablet formulations, with and without naloxone, and from studies of sublingual administration of a more bioavailable ethanolic solution of buprenorphine.
Buprenorphine and naloxone sublingual tablets have been studied in 575 patients, buprenorphine HCl tablets in 1834 patients and Buprenorphine Sublingual solutions in 2470 patients. A total of 1270 females have received buprenorphine in clinical trials. Dosing recommendations are based on data from one trial of both tablet formulations and two trials of the ethanolic solution. All trials used buprenorphine in conjunction with psychosocial counseling as part of a comprehensive addiction treatment program. There have been no clinical studies conducted to assess the efficacy of buprenorphine as the only component of treatment.
In a double blind placebo- and active controlled study, 326 heroin-addicted subjects were randomly assigned to either 16 mg buprenorphine and naloxone sublingual tablets per day, 16 mg buprenorphine HCl sublingual tablets per day or placebo tablets. For subjects randomized to either active treatment, dosing began with one 8 mg tablet of buprenorphine HCl sublingual tablet on Day 1, followed by 16 mg (two 8 mg tablets) of buprenorphine HCl sublingual tablets on Day 2. On Day 3, those randomized to receive buprenorphine and naloxone sublingual tablets were switched to the combination tablet. Subjects randomized to placebo received one placebo tablet on Day 1 and two placebo tablets per day thereafter for four weeks. Subjects were seen daily in the clinic (Monday through Friday) for dosing and efficacy assessments. Take-home doses were provided for weekends. Subjects were instructed to hold the medication under the tongue for approximately 5 to 10 minutes until completely dissolved. Subjects received one hour of individual counseling per week and a single session of HIV education. The primary study comparison was to assess the efficacy of buprenorphine HCl sublingual tablets and buprenorphine and naloxone sublingual tablets individually against placebo. The percentage of thrice-weekly urine samples that were negative for non-study opioids was statistically higher for both buprenorphine HCl sublingual tablets and buprenorphine and naloxone sublingual tablets, than for placebo.
In a double-blind, double-dummy, parallel-group study comparing buprenorphine ethanolic solution to a full agonist active control, 162 subjects were randomized to receive the ethanolic sublingual solution of buprenorphine at 8 mg/day (a dose which is roughly comparable to a dose of 12 mg/day of buprenorphine HCl sublingual tablets or buprenorphine and naloxone sublingual tablets), or two relatively low doses of active control, one of which was low enough to serve as an alternative to placebo, during a 3 to 10-day induction phase, a 16-week maintenance phase and a 7-week detoxification phase. Buprenorphine was titrated to maintenance dose by Day 3; active control doses were titrated more gradually.
Maintenance dosing continued through Week 17, and then medications were tapered by approximately 20 to 30% per week over Weeks 18 to 24, with placebo dosing for the last two weeks. Subjects received individual and/or group counseling weekly.
Based on retention in treatment and the percentage of thrice-weekly urine samples negative for non-study opioids, buprenorphine was more effective than the low dose of the control, in keeping heroin addicts in treatment and in reducing their use of opioids while in treatment. The effectiveness of buprenorphine, 8 mg per day was similar to that of the moderate active control dose, but equivalence was not demonstrated.
In a dose-controlled, double-blind, parallel-group, 16-week study, 731 subjects were randomized to receive one of four doses of buprenorphine ethanolic solution. Buprenorphine was titrated to maintenance doses over 1 to 4 days (Table 2) and continued for 16 weeks. Subjects received at least one session of AIDS education and additional counseling ranging from one hour per month to one hour per week, depending on site.
| Target dose of Buprenorphine * | Induction Dose | Maintenance dose | ||
|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | ||
| ||||
| 1 mg | 1 mg | 1 mg | 1 mg | 1 mg |
| 4 mg | 2 mg | 4 mg | 4 mg | 4 mg |
| 8 mg | 2 mg | 4 mg | 8 mg | 8 mg |
| 16 mg | 2 mg | 4 mg | 8 mg | 16 mg |
Based on retention in treatment and the percentage of thrice-weekly urine samples negative for non-study opioids, the three highest tested doses were superior to the 1 mg dose. Therefore, this study showed that a range of buprenorphine doses may be effective. The 1 mg dose of Buprenorphine Sublingual solution can be considered to be somewhat lower than a 2 mg tablet dose. The other doses used in the study encompass a range of tablet doses from approximately 6 mg to approximately 24 mg.
Buprenorphine HCl sublingual tablets is indicated for the treatment of opioid dependence.
Buprenorphine HCl sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine.
Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of deaths have occurred when addicts have intravenously misused buprenorphine, usually with benzodiazepines concomitantly. Deaths have also been reported in association with concomitant administration of buprenorphine with other depressants such as alcohol or other opioids. Patients should be warned of the potential danger of the self-administration of benzodiazepines or other depressants while under treatment with buprenorphine HCl sublingual tablets.
IN THE CASE OF OVERDOSE, THE PRIMARY MANAGEMENT SHOULD BE THE RE-ESTABLISHMENT OF ADEQUATE VENTILATION WITH MECHANICAL ASSISTANCE OF RESPIRATION, IF REQUIRED.
Buprenorphine HCl sublingual tablets should be used with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression).
Patients receiving buprenorphine in the presence of other narcotic analgesics, general anesthetics, benzodiazepines, phenothiazines, other tranquilizers, sedative/hypnotics or other CNS depressants (including alcohol) may exhibit increased CNS depression. When such combined therapy is contemplated, reduction of the dose of one or both agents should be considered.
Buprenorphine is a partial agonist at the mu-opiate receptor and chronic administration produces dependence of the opioid type, characterized by withdrawal upon abrupt discontinuation or rapid taper. The withdrawal syndrome is milder than seen with full agonists, and may be delayed in onset.
Cases of cytolytic hepatitis and hepatitis with jaundice have been observed in the addict population receiving buprenorphine both in clinical trials and in post-marketing adverse event reports. The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy. In many cases, the presence of pre-existing liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus, concomitant usage of other potentially hepatotoxic drugs, and ongoing injecting drug use may have played a causative or contributory role. In other cases, insufficient data were available to determine the etiology of the abnormality. The possibility exists that buprenorphine had a causative or contributory role in the development of the hepatic abnormality in some cases. Measurements of liver function tests prior to initiation of treatment is recommended to establish a baseline. Periodic monitoring of liver function tests during treatment is also recommended. A biological and etiological evaluation is recommended when a hepatic event is suspected. Depending on the case, the drug should be carefully discontinued to prevent withdrawal symptoms and a return to illicit drug use, and strict monitoring of the patient should be initiated.
Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience. The most common signs and symptoms include rashes, hives, and pruritus. Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported. A history of hypersensitivity to buprenorphine is a contraindication to buprenorphine HCl sublingual tablet use.
Buprenorphine HCl sublingual tablets may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery, especially during drug induction and dose adjustment. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that buprenorphine therapy does not adversely affect their ability to engage in such activities. Like other opioids, buprenorphine HCl sublingual tablets may produce orthostatic hypotension in ambulatory patients.
Buprenorphine HCl sublingual tablets, like other potent opioids, may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions and other circumstances where cerebrospinal pressure may be increased. Buprenorphine HCl sublingual tablets can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.
Buprenorphine HCl sublingual tablets should be administered with caution in elderly or debilitated patients and those with severe impairment of hepatic, pulmonary, or renal function; myxedema or hypothyroidism, adrenal cortical insufficiency (e.g., Addison's disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; or kyphoscoliosis.
The effect of hepatic impairment on the pharmacokinetics of buprenorphine is unknown. Since buprenorphine is extensively metabolized, the plasma levels will be expected to be higher in patients with moderate and severe hepatic impairment. Therefore, dosage should be adjusted and patients should be watched for symptoms of precipitated opioid withdrawal.
Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.
As with other mu-opioid receptor agonists, the administration of buprenorphine HCl sublingual tablets may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4. Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and HIV protease inhibitors (e.g., ritonavir, indinavir and saquinavir) should have their dose of buprenorphine HCl sublingual tablets adjusted.
Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines. There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts. In many of these cases, buprenorphine was misused by self-injection of crushed buprenorphine HCl sublingual tablets. Buprenorphine HCl sublingual tablets should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse. Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with buprenorphine HCl sublingual tablets.
Patients should inform their family members that, in the event of emergency, the treating physician or emergency room staff should be informed that the patient is physically dependent on narcotics and that the patient is being treated with buprenorphine HCl sublingual tablets.
Patients should be cautioned that a serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as buprenorphine HCl sublingual tablets.
Buprenorphine HCl sublingual tablets may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery, especially during drug induction and dose adjustment. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that buprenorphine therapy does not adversely affect their ability to engage in such activities. Like other opioids, buprenorphine HCl sublingual tablets may produce orthostatic hypotension in ambulatory patients.
Patients should consult their physician if other prescription medications are currently being used or are prescribed for future use.
Carcinogenicity studies of buprenorphine were conducted in Sprague-Dawley rats and CD-1 mice. Buprenorphine was administered in the diet to rats at doses of 0.6, 5.5, and 56 mg/kg/day (estimated exposure was approximately 0.4, 3 and 35 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis) for 27 months. Statistically significant dose-related increases in testicular interstitial (Leydig's) cell tumors occurred, according to the trend test adjusted for survival. Pair-wise comparison of the high dose against control failed to show statistical significance. In an 86-week study in CD-1 mice, buprenorphine was not carcinogenic at dietary doses up to 100 mg/kg/day (estimated exposure was approximately 30 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis).
Buprenorphine was studied in a series of tests utilizing gene, chromosome, and DNA interactions in both prokaryotic and eukaryotic systems. Results were negative in yeast (Saccharomyces cerevisiae) for recombinant, gene convertant, or forward mutations; negative in Bacillus subtilis "rec" assay, negative for clastogenicity in CHO cells, Chinese hamster bone marrow and spermatogonia cells, and negative in the mouse lymphoma L5178Y assay. Results were equivocal in the Ames test: negative in studies in two laboratories, but positive for frame shift mutation at a high dose (5 mg/plate) in a third study. Results were positive in the Green-Tweets (E. coli) survival test, positive in a DNA synthesis inhibition (DSI) test with testicular tissue from mice, for both in vivo and in vitro incorporation of [3H]thymidine, and positive in unscheduled DNA synthesis (UDS) test using testicular cells from mice.
Reproduction studies of buprenorphine in rats demonstrated no evidence of impaired fertility at daily oral doses up to 80 mg/kg/day (estimated exposure was approximately 50 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis) or up to 5 mg/kg/day im or sc (estimated exposure was approximately 3 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis).
Buprenorphine was not teratogenic in rats or rabbits after im or sc doses up to 5 mg/kg/day (estimated exposure was approximately 3 and 6 times, respectively, the recommended human daily sublingual dose of 16 mg on a mg/m2 basis), after iv doses up to 0.8 mg/kg/day (estimated exposure was approximately 0.5 times and equal to, respectively, the recommended human daily sublingual dose of 16 mg on a mg/m2 basis), or after oral doses up to 160 mg/kg/day in rats (estimated exposure was approximately 95 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis) and 25 mg/kg/day in rabbits (estimated exposure was approximately 30 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis). Significant increases in skeletal abnormalities (e.g., extra thoracic vertebra or thoraco-lumbar ribs) were noted in rats after sc administration of 1 mg/kg/day and up (estimated exposure was approximately 0.6 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis), but were not observed at oral doses up to 160 mg/kg/day. Increases in skeletal abnormalities in rabbits after im administration of 5 mg/kg/day (estimated exposure was approximately 6 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis) or oral administration of 1 mg/kg/day or greater (estimated exposure was approximately equal to the recommended human daily sublingual dose of 16 mg on a mg/m2 basis) were not statistically significant.
In rabbits, buprenorphine produced statistically significant pre-implantation losses at oral doses of 1 mg/kg/day or greater and post-implantation losses that were statistically significant at iv doses of 0.2 mg/kg/day or greater (estimated exposure was approximately 0.3 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis).
There are no adequate and well-controlled studies of buprenorphine HCl sublingual tablets in pregnant women. Buprenorphine HCl sublingual tablets should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
Dystocia was noted in pregnant rats treated im with buprenorphine 5 mg/kg/day (approximately 3 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis). Both fertility and peri- and postnatal development studies with buprenorphine in rats indicated increases in neonatal mortality after oral doses of 0.8 mg/kg/day and up (approximately 0.5 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis), after im doses of 0.5 mg/kg/day and up (approximately 0.3 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis), and after sc doses of 0.1 mg/kg/day and up (approximately 0.06 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis). Delays in the occurrence of righting reflex and startle response were noted in rat pups at an oral dose of 80 mg/kg/day (approximately 50 times the recommended human daily sublingual dose of 16 mg on a mg/m2 basis).
Neonatal withdrawal has been reported in the infants of women treated with buprenorphine HCl sublingual tablets during pregnancy. From post-marketing reports, the time to onset of neonatal withdrawal symptoms ranged from Day 1 to Day 8 of life with most occurring on Day 1. Adverse events associated with neonatal withdrawal syndrome included hypertonia, neonatal tremor, neonatal agitation, and myoclonus. There have been rare reports of convulsions and in one case, apnea and bradycardia were also reported.
An apparent lack of milk production during general reproduction studies with buprenorphine in rats caused decreased viability and lactation indices. Use of high doses of sublingual buprenorphine in pregnant women showed that buprenorphine passes into the mother's milk. Breast-feeding is therefore not advised in mothers treated with buprenorphine HCl sublingual tablets.
Buprenorphine HCl sublingual tablets is not recommended for use in pediatric patients. The safety and effectiveness of buprenorphine HCl sublingual tablets in patients below the age of 16 have not been established.
The safety of Buprenorphine Sublingual tablets has been evaluated in clinical trials using buprenorphine HCl sublingual tablets or Buprenorphine Sublingual solutions, and supported by other trials in 497 opioid-dependent subjects treated by buprenorphine and naloxone sublingual tablets. In total, safety data are available from 3214 opioid-dependent subjects exposed to buprenorphine at doses in the range used in treatment of opioid addiction.
Few differences in adverse event profile were noted between buprenorphine and naloxone sublingual tablets and buprenorphine HCl sublingual tablets or buprenorphine administered as a sublingual solution.
In a comparative study, adverse event profiles were similar for subjects treated with 16 mg buprenorphine and naloxone sublingual tablets or 16 mg buprenorphine HCl sublingual tablets. The following adverse events were reported to occur by at least 5% of patients in a 4-week study (Table 3).
| N(%) | N(%) | N(%) | |
|---|---|---|---|
| Body System /Adverse Event (COSTART Terminology) | buprenorphine and naloxone sublingual tablets 16 mg/day N=107 | Buprenorphine HCl sublingual tablets 16 mg/day N=103 | Placebo N=107 |
| Body as a Whole | |||
| Asthenia | 7 (6.5%) | 5 (4.9%) | 7 (6.5%) |
| Chills | 8 (7.5%) | 8 (7.8%) | 8 (7.5%) |
| Headache | 39 (36.4%) | 30 (29.1%) | 24 (22.4%) |
| Infection | 6 (5.6%) | 12 (11.7%) | 7 (6.5%) |
| Pain | 24 (22.4%) | 19 (18.4%) | 20 (18.7%) |
| Pain Abdomen | 12 (11.2%) | 12 (11.7%) | 7 (6.5%) |
| Pain Back | 4 (3.7%) | 8 (7.8%) | 12 (11.2%) |
| Withdrawal Syndrome | 27 (25.2%) | 19 (18.4%) | 40 (37.4%) |
| Cardiovascular System | |||
| Vasodilation | 10 (9.3%) | 4 (3.9%) | 7 (6.5%) |
| Digestive System | |||
| Constipation | 13 (12.1%) | 8 (7.8%) | 3 (2.8%) |
| Diarrhea | 4 (3.7%) | 5 (4.9%) | 16 (15.0%) |
| Nausea | 16 (15.0%) | 14 (13.6%) | 12 (11.2%) |
| Vomiting | 8 (7.5%) | 8 (7.8%) | 5 (4.7%) |
| Nervous System | |||
| Insomnia | 15 (14.0%) | 22 (21.4%) | 17 (15.9%) |
| Respiratory System | |||
| Rhinitis | 5 (4.7%) | 10 (9.7%) | 14 (13.1%) |
| Skin and Appendages | |||
| Sweating | 15 (14.0%) | 13 (12.6%) | 11 (10.3%) |
The adverse event profile of buprenorphine was also characterized in the dose-controlled study of buprenorphine solution, over a range of doses in four months of treatment. Table 4 shows adverse events reported by at least 5% of subjects in any dose group in the dose-controlled study.
| Body System/ Adverse Event (COSTART Terminology) | Buprenorphine Dose* | ||||
|---|---|---|---|---|---|
| Very Low* (N=184) | Low* (N=180) | Moderate* (N=186) | High* (N=181) | Total* (N=731) | |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| |||||
| Body as a Whole | |||||
| Abscess | 9 (5%) | 2 (1%) | 3 (2%) | 2 (1%) | 16 (2%) |
| Asthenia | 26 (14%) | 28 (16%) | 26 (14%) | 24 (13%) | 104 (14%) |
| Chills | 11 (6%) | 12 (7%) | 9 (5%) | 10 (6%) | 42 (6%) |
| Fever | 7 (4%) | 2 (1%) | 2 (1%) | 10 (6%) | 21 (3%) |
| Flu Syndrome | 4 (2%) | 13 (7%) | 19 (10%) | 8 (4%) | 44 (6%) |
| Headache | 51 (28%) | 62 (34%) | 54 (29%) | 53 (29%) | 220 (30%) |
| Infection | 32 (17%) | 39 (22%) | 38 (20%) | 40 (22%) | 149 (20%) |
| Injury Accidental | 5 (3%) | 10 (6%) | 5 (3%) | 5 (3%) | 25 (3%) |
| Pain | 47 (26%) | 37 (21%) | 49 (26%) | 44 (24%) | 177 (24%) |
| Pain Back | 18 (10%) | 29 (16%) | 28 (15%) | 27 (15%) | 102 (14%) |
| Withdrawal Syndrome | 45 (24%) | 40 (22%) | 41 (22%) | 36 (20%) | 162 (22%) |
| Digestive System | |||||
| Constipation | 10 (5%) | 23 (13%) | 23 (12%) | 26 (14%) | 82 (11%) |
| Diarrhea | 19 (10%) | 8 (4%) | 9 (5%) | 4 (2%) | 40 (5%) |
| Dyspepsia | 6 (3%) | 10 (6%) | 4 (2%) | 4 (2%) | 24 (3%) |
| Nausea | 12 (7%) | 22 (12%) | 23 (12%) | 18 (10%) | 75 (10%) |
| Vomiting | 8 (4%) | 6 (3%) | 10 (5%) | 14 (8%) | 38 (5%) |
| Nervous System | |||||
| Anxiety | 22 (12%) | 24 (13%) | 20 (11%) | 25 (14%) | 91 (12%) |
| Depression | 24 (13%) | 16 (9%) | 25 (13%) | 18 (10%) | 83 (11%) |
